2023-05-16 02:38:00
LOS ANGELES, United States, May 15 (Xinhua) — The United States has launched the clinical trial phase of an experimental universal influenza vaccine developed by researchers from the United States Institutes of Health (NIH), the agency announced on Monday.
The study began recruiting volunteers at Duke University in Durham, North Carolina. This phase 1 trial will test the experimental vaccine, known as H1ssF-3928 mRNA-LNP, for safety and ability to induce an immune response, according to the NIH.
The trial will include up to 50 healthy volunteers between the ages of 18 and 49. Three groups of ten participants will be vaccinated with 10, 25 and 50 micrograms of the experimental vaccine respectively.
After evaluating the data to determine the optimal dosage, ten additional participants will be recruited to receive it.
The study will also include a group of participants who will receive the current quadrivalent seasonal influenza vaccine. This will provide researchers with a direct point of comparison between the candidate vaccine and available seasonal flu vaccines for immunogenicity and safety, according to the NIH. END
1684207122
#U.S #begins #clinical #trial #phase #universal #messenger #RNA #flu #vaccine #Xinhua #English.news.cn
